Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients

Antimicrob Agents Chemother. 2017 Oct 24;61(11):e00608-17. doi: 10.1128/AAC.00608-17. Print 2017 Nov.

Abstract

Aspergillus fumigatus azole resistance has emerged as a global health problem. We evaluated the in vitro antifungal susceptibility of 221 clinical A. fumigatus isolates according to CLSI guidelines. Sixty-one isolates exhibiting MICs at the epidemiological cutoff value (ECV) for itraconazole or above the ECV for any triazole were checked for CYP51A mutations. No mutations were documented, even for the isolates (1.8%) with high voriconazole MICs, indicating that triazoles may be used safely to treat aspergillosis in Brazil.

Keywords: A. fumigatus; Brazil; antifungal resistance; invasive aspergillosis; triazole resistance.

MeSH terms

  • Antifungal Agents / therapeutic use*
  • Aspergillosis / drug therapy*
  • Aspergillus fumigatus / drug effects*
  • Aspergillus fumigatus / isolation & purification
  • Brazil
  • Drug Resistance, Fungal / genetics*
  • Humans
  • Invasive Fungal Infections / drug therapy*
  • Itraconazole / therapeutic use*
  • Microbial Sensitivity Tests
  • Retrospective Studies
  • Voriconazole / therapeutic use*

Substances

  • Antifungal Agents
  • Itraconazole
  • Voriconazole